Adipose Tissue Dysfunction and Obesity-Related Male Hypogonadism

Int J Mol Sci. 2022 Jul 25;23(15):8194. doi: 10.3390/ijms23158194.

Abstract

Obesity is a chronic illness associated with several metabolic derangements and comorbidities (i.e., insulin resistance, leptin resistance, diabetes, etc.) and often leads to impaired testicular function and male subfertility. Several mechanisms may indeed negatively affect the hypothalamic-pituitary-gonadal health, such as higher testosterone conversion to estradiol by aromatase activity in the adipose tissue, increased ROS production, and the release of several endocrine molecules affecting the hypothalamus-pituitary-testis axis by both direct and indirect mechanisms. In addition, androgen deficiency could further accelerate adipose tissue expansion and therefore exacerbate obesity, which in turn enhances hypogonadism, thus inducing a vicious cycle. Based on these considerations, we propose an overview on the relationship of adipose tissue dysfunction and male hypogonadism, highlighting the main biological pathways involved and the current therapeutic options to counteract this condition.

Keywords: adipose tissue; hypogonadism; infertility; obesity; reproductive dysfunction.

Publication types

  • Review

MeSH terms

  • Adipose Tissue
  • Humans
  • Hypogonadism* / complications
  • Hypogonadism* / drug therapy
  • Insulin Resistance*
  • Male
  • Obesity / drug therapy
  • Testis
  • Testosterone / therapeutic use

Substances

  • Testosterone

Grants and funding

This work was carried out with support from the ‘Fondazione per la Ricerca Biomedica Saverio e Isabella Cianciola’, Italy. The APC was funded by funds of the Specialization School in Endocrinology and Metabolic Diseases, University of Bari Aldo Moro.